Therasense Revisited: In re Rosuvastatin Calcium Patent Litigation and the Interplay Between Reissue and Inequitable Conduct

Reproduced with permission from Pharmaceutical Law & Industry Report, 11 PLIR 482 (Apr. 12, 2013). Copyright 2013 by The Bureau of National Affairs, Inc. (800-372-1033) http://www.bna.com.

The author states that the Therasense high bar on deceptive intent carried over to the reissue context in Rosuvastatin Calcium Patent Litigation and questions whether a change to the relevant statute in the America Invents Act will have meaningful impact on the inequitable conduct defense.